MedTrace Logo

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach

NCT05295992 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-06

No results posted yet for this study

Summary

This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Conditions

  • Muscle-Invasive Bladder Carcinoma

Interventions

DEVICE

Varian Ethos Adaptive Radiation Therapy

Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.

Sponsors & Collaborators

  • Herlev Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Varian, a Siemens Healthineers Company

    lead INDUSTRY

Principal Investigators

  • Katrine Storm, MD · Herlev Hospital, Copenhagen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05295992 on ClinicalTrials.gov